Successful treatment of acute promyelocytic leukemia in a patient on hemodialysis

Clin Exp Nephrol. 2011 Jun;15(3):434-437. doi: 10.1007/s10157-011-0405-5. Epub 2011 Feb 5.


Acute promyelocytic leukemia (APL) has the best prognosis among acute leukemias, but there is little data about APL in patients on hemodialysis. A 64-year-old hemodialysis patient was successfully treated for APL by induction therapy with all-trans retinoic acid (ATRA), three courses of consolidation therapy with Ara-C, mitomycin C (MIT), daunorubicin (DNR), and idarubicin (IDR), and maintenance therapy with ATRA. Complete remission has been maintained for 42 months in this patient. With dose modification, ATRA and chemotherapy may be safely given to patients on hemodialysis.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Cytarabine / administration & dosage
  • Daunorubicin / therapeutic use
  • Female
  • Humans
  • Idarubicin / therapeutic use
  • Kidney Failure, Chronic / complications*
  • Leukemia, Promyelocytic, Acute / drug therapy*
  • Middle Aged
  • Mitomycin / administration & dosage
  • Remission Induction
  • Renal Dialysis
  • Tretinoin / administration & dosage


  • Cytarabine
  • Mitomycin
  • Tretinoin
  • Idarubicin
  • Daunorubicin